SCHEMBL4296906

SCHEMBL4296906

CCN1CCN(Cc2c(F)cc(-n3ccc4cnc(Nc5ccc(F)c(C)c5)nc43)cc2F)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 2/20 0.45
JAK2 O60674 12/20 0.45
BRD4 O60885 12/20 0.45
EGFR P00533 1/20 0.44
PDGFRB P09619 1/20 0.44
FGFR1 P11362 1/20 0.44
SRC P12931 1/20 0.44
PDGFRA P16234 1/20 0.44
STAT5A P42229 1/20 0.44
ACVR1 Q04771 1/20 0.44
PKMYT1 Q99640 1/20 0.44
JAK1 P23458 2/20 0.43
BRD2 P25440 2/20 0.43
JAK3 P52333 2/20 0.43
BRD3 Q15059 2/20 0.43
BRDT Q58F21 2/20 0.43
EIF2AK4 Q9P2K8 1/20 0.42
AXL P30530 1/20 0.42
STAT6 P42226 1/20 0.42
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27824866 0.95 HTT (0.48) RPS6KA3JAK2BRD4JAK1BRD2
SCHEMBL1655066 0.91 AXL (0.47) RPS6KA3JAK2BRD4EGFRPDGFRB
SCHEMBL1655869 0.90 RPS6KA3 (0.54) RPS6KA3JAK2BRD4EGFRPDGFRB
SCHEMBL4284131 0.90 JAK2 (0.48) RPS6KA3JAK2BRD4EGFRPDGFRB
SCHEMBL4295870 0.90 JAK2 (0.56) RPS6KA3JAK2BRD4EGFRPDGFRB
SCHEMBL4288934 0.89 RPS6KA3 (0.47) RPS6KA3JAK2BRD4EGFRPDGFRB
SCHEMBL4288944 0.89 RPS6KA3 (0.45) RPS6KA3JAK2BRD4EGFRPDGFRB
SCHEMBL1654555 0.89 EGFR (0.43) RPS6KA3JAK2BRD4EGFRPDGFRB
SCHEMBL1654797 0.88 RPS6KA3 (0.54) RPS6KA3JAK2BRD4JAK1BRD2
SCHEMBL27824885 0.87 JAK2 (0.45) RPS6KA3JAK2BRD4JAK1BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US claimed
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed
WO-2009098236-A1 PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 RPS6KA3 303/4885JAK2 2/4885BRD4 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.